Molecular profiling enabled targeted treatment that significantly improved survival in advanced cholangiocarcinoma. Learn ...

NDA supported by results from a Phase II registration trial in China —— Second most common form of liver cancer after hepatocellular carcinoma, ...

China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma: Hong Kong, Shanghai Wednesday, December ...

NDA supported by results from a Phase II registration trial in China - - Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison ...

A decade-long retrospective study shows IgG4-related cholangitis responds well to steroids, with low mortality and no ...

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status.

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing ...

HUTCHMED (China) ( ($HK:0013) ) has issued an update. HUTCHMED has announced that China’s National Medical Products Administration has accepted ...

The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.

Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...